In human conditions such as obesity, a low-grade inflammation with increased levels of pro-inflammatory markers is present; some inflammatory cytokines (i.e., interleukin (IL)-6, IL-18) are involved in BMI increase, metabolic and cardiovascular diseases [8–10] and anti-inflammatory interventions can, at least in part, counteract metabolic dysfunctions. Here, IL18 is linked to obesity disorder.